Cargando…

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Rathi, Nityam, Maughan, Benjamin L., Agarwal, Neeraj, Swami, Umang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797268/ https://www.ncbi.nlm.nih.gov/pubmed/35117054 http://dx.doi.org/10.21037/tcr.2019.07.02

Ejemplares similares

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
por: Swami, Umang, et al.
Publicado: (2021)

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice
por: Gebrael, Georges, et al.
Publicado: (2023)

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma
por: Li, Haoran, et al.
Publicado: (2023)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro
por: Campbell, Steven C., et al.
Publicado: (2022)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
por: Stenehjem, David D., et al.
Publicado: (2019)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies
por: Guha, Avirup, et al.
Publicado: (2022)

More Than Two HANDs to Tango
por: Kolson, Dennis, et al.
Publicado: (2013)

Lipoprotein secretion: It takes two to TANGO
por: Pfeffer, Suzanne R.
Publicado: (2016)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0
por: Gebrael, Georges, et al.
Publicado: (2023)

Tregs tango with killer cells in acute infection
por: Sun, Xiang, et al.
Publicado: (2022)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Editorial Commentary: It Takes Two to Tango: The Shared Decision of Return to Sport After Meniscal Transplantation
por: Grassi, Alberto, et al.
Publicado: (2020)

Clinical Outcomes of Patient Subgroups in the TANGO II Study
por: Bhowmick, Tanaya
Publicado: (2021)

New insights into protein secretion: TANGO1 runs rings around the COPII coat
por: Glick, Benjamin S.
Publicado: (2017)

It takes two to tango in the microenvironment!
por: Ursini-Siegel, Josie, et al.
Publicado: (2013)

A Solo Dance or a Tango?
por: Wan, Yulin, et al.
Publicado: (2019)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities
por: Sirohi, Deepika, et al.
Publicado: (2018)

Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma
por: Grünwald, Viktor, et al.
Publicado: (2020)

Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches
por: Campbell, Patrick, et al.
Publicado: (2023)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Tango therapy for Parkinson's disease: Effects of rush elemental tango therapy
por: Koh, Youngsoon, et al.
Publicado: (2020)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
por: Dawsey, Scott J., et al.
Publicado: (2021)

Gauchos and ochos: a Wee1-Cdk tango regulating mitotic entry
por: Enders, Greg H
Publicado: (2010)

Tandem Inhibition of PKC in Diαβetic Nephropathy: It Takes Two to Tango?
por: Thallas-Bonke, Vicki, et al.
Publicado: (2013)

Two to tango: endothelial cell TMEM16 scramblases drive coagulation and thrombosis
por: Filep, János G.
Publicado: (2023)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

The tango of ROS and p53 in tissue stem cells
por: Chen, Youguo, et al.
Publicado: (2018)

Management of metastatic renal cell carcinoma: The complexity of choice
por: Brown, Jacqueline T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ng5m86aufg0gvs524aeaqn6bpi